[8-K] bioAffinity Technologies, Inc. Reports Material Event

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. (BIAF) filed an 8-K reporting that it furnished a press release containing financial information for the quarter ended September 30, 2025. The company stated the press release is provided under Item 2.02 and is furnished, not filed, and will not be incorporated by reference into other SEC filings.

Exhibits include 99.1 (the press release dated November 14, 2025) and 104 (Cover Page Interactive Data File). The company’s securities listed are Common Stock (BIAF) and Tradeable Warrants (BIAFW) on The Nasdaq Stock Market LLC.

false 0001712762 0001712762 2025-11-14 2025-11-14 0001712762 BIAF:CommonStockParValue.007PerShareMember 2025-11-14 2025-11-14 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

BIOAFFINITY TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $.007 per share		BIAF		The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operation and Financial Condition.

On November 14, 2025, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for its quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K:

Exhibit		Description
99.1		Press Release issued by bioAffinity Technologies, Inc. dated November 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	(Registrant)
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did BIAF disclose in this 8-K?

The company furnished a press release with financial information for the quarter ended September 30, 2025 under Item 2.02.

Is the press release considered filed with the SEC?

No. It is expressly stated as furnished, not filed, and is not subject to Section 18 liabilities.

Will the press release be incorporated by reference into other filings?

No. The company states it will not be incorporated by reference into any SEC filing.

Which exhibits accompany the 8-K?

Exhibit 99.1 is the press release dated November 14, 2025, and Exhibit 104 is the Cover Page Interactive Data File.

Which exchanges and symbols does BIAF use?

Common Stock trades as BIAF and Tradeable Warrants as BIAFW on The Nasdaq Stock Market LLC.

What period does the financial information cover?

The quarter ended September 30, 2025.